CoChat

Low-dose PLX5622 treatment prevents neuroinflammatory and neurocognitive sequelae after sepsis

Open access
Mein, Nils, von Stackelberg, Nikolai, Wickel, Jonathan, Geis, Christian, Chung, Ha-Yeun · 2023 · Journal of Neuroinflammation

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Background: Sepsis-associated encephalopathy (SAE) is characterized by symptoms of delirium including hallucinations, impaired concentration, agitation, or coma and is associated with poor outcome in the early phase of sepsis. In addition, sepsis survivors often suffer from persisting memory deficits and impaired executive functions. Recent studies provide evidence that microglia are involved in the pathophysiology of SAE. Methods: Here, we investigated whether pharmacological depletion of microglia using PLX5622 (1200 ppm or 300 ppm) in the acute phase of sepsis is able to prevent long-term neurocognitive decline in a male mouse model of polymicrobial sepsis or lipopolysaccharide-induced sterile neuroinflammation. Therefore, we performed the novel object recognition test at different time points after sepsis to address hippocampus-dependent learning. To further assess synapse engulfment in microglia, colocalization analysis was performed using high-resolution 3D Airyscan imaging of Iba1 and Homer1. We also investigated the effect of PLX5622 on acute astrocyte and chronic microglia proliferation in the hippocampus after sepsis induction using immunofluorescence staining. Results: High-dose application of the colony stimulating factor 1 receptor (CSF1R) inhibitor PLX5622 (1200 ppm) seven days prior to sepsis induction lead to 70–80% microglia reduction but resulted in fatal outcome of bacterial sepsis or LPS induced inflammation. This is likely caused by severely compromised host immune response upon PLX5622-induced depletion of peripheral monocytes and macrophages. We therefore tested partial microglia depletion using a low-dose of PLX5622 (300 ppm) for seven days prior to sepsis which resulted in an increased survival in comparison to littermates subjected to high-dose CSF1R inhibiton and to a stable microglia reduction of ~ 40%. This partial microglia depletion in the acute stage of sepsis largely prevented the engulfment and microglia-induced stripping of postsynaptic terminals. In addition, PLX5622 low-dose microglia depletion attenuated acute astrogliosis as well as long-term microgliosis and prevented long-term neurocognitive decline after experimental sepsis. Conclusions: We conclude that partial microglia depletion before the induction of sepsis may be sufficient to attenuate long-term neurocognitive dysfunction. Application of PLX5622 (300 ppm) acts by reducing microglia-induced synaptic attachement/engulfment and preventing chronic microgliosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12974-023-02975-8

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 High-dose PLX5622 pretreatment causes poor outcome in LPS and PCI induced systemic inflammation. A Timeline of experiment: mice were randomized to AIN or PLX5622 (1200 ppm) treatment seven days prior to PCI induction. B Quantitative analysis of Iba1-positive microglia in the CA1 region of the hippocampus at day 0 following AIN or PLX5622 treatment (n = 3 animals/group; n = 3 images/animal, Student’s t-test). Representative confocal overview images of microglia in the CA1 region after pretreatment with either AIN or high-dose PLX5622 (1200 ppm) on day 0. Scale bar 200 µm. C Kaplan–Meier analysis of PCI induced sepsis following AIN or high-dose PLX5622 treatment for seven days (AIN: PCI: n = 21 animals/group, PLX5622: PCI: n = 6 animals/group, log-rank test). D Representative photograph of cerebral microbleeds in mice pretreated with high-dose PLX5622 for seven days followed by PCI induction. E Timeline of experiment: mice were randomized to AIN or high-dose PLX5622 (1200 ppm) treatment seven days prior to induction of systemic inflammation by LPS. F Kaplan–Meier analysis of LPS induced systemic inflammation following AIN and high-dose PLX5622 pretreatment for 7 consecutive days (AIN: LPS: n = 14 animals/group and PLX5622: LPS: n = 6 animals/group). Data are presented as mean ± SEM. Individual values are presented as small dots and each circle represents an average of one mouse; individual values and averages are color coded
Fig. 1 High-dose PLX5622 pretreatment causes poor outcome in LPS and PCI induced systemic inflammation. A Timeline of experiment: mice were randomized to AIN or PLX5622 (1200 ppm) treatment seven days prior to PCI induction. B Quantitative analysis of Iba1-positive microglia in the CA1 region of the hippocampus at day 0 following AIN or PLX5622 treatment (n = 3 animals/group; n = 3 images/animal, Student’s t-test). Representative confocal overview images of microglia in the CA1 region after pretreatment with either AIN or high-dose PLX5622 (1200 ppm) on day 0. Scale bar 200 µm. C Kaplan–Meier analysis of PCI induced sepsis following AIN or high-dose PLX5622 treatment for seven days (AIN: PCI: n = 21 animals/group, PLX5622: PCI: n = 6 animals/group, log-rank test). D Representative photograph of cerebral microbleeds in mice pretreated with high-dose PLX5622 for seven days followed by PCI induction. E Timeline of experiment: mice were randomized to AIN or high-dose PLX5622 (1200 ppm) treatment seven days prior to induction of systemic inflammation by LPS. F Kaplan–Meier analysis of LPS induced systemic inflammation following AIN and high-dose PLX5622 pretreatment for 7 consecutive days (AIN: LPS: n = 14 animals/group and PLX5622: LPS: n = 6 animals/group). Data are presented as mean ± SEM. Individual values are presented as small dots and each circle represents an average of one mouse; individual values and averages are color codedCC BY · PubMed Central
Fig. 2 Partial microlgia depletion by low-dose PLX5622 only slightly affects the course of sepsis. A Timeline of experiment: mice were randomized to AIN or low-dose PLX5622 (300 ppm) treatment seven days prior to PCI. After PCI (day 0) all mice received standard AIN chow. B Quantitative analysis of Iba1-positive microglia in the CA1 region of the hippocampus following AIN or PLX5622 treatment at day 0 (n = 3 animals/group; n = 15 images/animal, Student’s t-test). Representative confocal overview and zoom-in images of Iba1-positive microglia in the CA1 region after pretreatment with either AIN or PLX5622 (300 ppm). Scale bar 20 µm and 200 µm. C Kaplan–Meier analysis of PCI induced systemic inflammation following AIN and low-dose PLX5622 between day 0 until day 38 (AIN-sham: n = 20, AIN-PCI: n = 42; PLX5622-sham: n = 20, PLX5622-PCI: n = 45, log-rank test: p < 0.0001). D Clinical severity score (AIN-sham: n = 20, AIN-PCI: n = 42; PLX5622-sham: n = 20, PLX5622-PCI: n = 45; the adapted two-tailed permutation test of Cohen (significance level of 5%) thereby accounting for the multiple-comparison problem has been performed. E Time dynamics in the development of clinical severity score until CSS ≥ 3 (AIN-PCI: n = 42, PLX5622-PCI: n = 45, Mann–Whitney-U-test). F Weight development during pretreatment of AIN or low-dose PLX5622 between day -7 until day 0 and during polymicrobial sepsis between day 0 and day 38 (AIN: sham: n = 20, PCI: n = 42; PLX5622: sham: n = 20, PCI: n = 45; day -7 until day 0: Curve-permutation test (two-tailed), p = 0.3780; day 0 until day 38: Curve-permutation test (two-tailed) with Benjamini–Hochberg correction. Data are presented as mean ± SEM. Individual values are presented as small dots and each circle represents an average of one mouse; individual values and averages are color coded
Fig. 2 Partial microlgia depletion by low-dose PLX5622 only slightly affects the course of sepsis. A Timeline of experiment: mice were randomized to AIN or low-dose PLX5622 (300 ppm) treatment seven days prior to PCI. After PCI (day 0) all mice received standard AIN chow. B Quantitative analysis of Iba1-positive microglia in the CA1 region of the hippocampus following AIN or PLX5622 treatment at day 0 (n = 3 animals/group; n = 15 images/animal, Student’s t-test). Representative confocal overview and zoom-in images of Iba1-positive microglia in the CA1 region after pretreatment with either AIN or PLX5622 (300 ppm). Scale bar 20 µm and 200 µm. C Kaplan–Meier analysis of PCI induced systemic inflammation following AIN and low-dose PLX5622 between day 0 until day 38 (AIN-sham: n = 20, AIN-PCI: n = 42; PLX5622-sham: n = 20, PLX5622-PCI: n = 45, log-rank test: p < 0.0001). D Clinical severity score (AIN-sham: n = 20, AIN-PCI: n = 42; PLX5622-sham: n = 20, PLX5622-PCI: n = 45; the adapted two-tailed permutation test of Cohen (significance level of 5%) thereby accounting for the multiple-comparison problem has been performed. E Time dynamics in the development of clinical severity score until CSS ≥ 3 (AIN-PCI: n = 42, PLX5622-PCI: n = 45, Mann–Whitney-U-test). F Weight development during pretreatment of AIN or low-dose PLX5622 between day -7 until day 0 and during polymicrobial sepsis between day 0 and day 38 (AIN: sham: n = 20, PCI: n = 42; PLX5622: sham: n = 20, PCI: n = 45; day -7 until day 0: Curve-permutation test (two-tailed), p = 0.3780; day 0 until day 38: Curve-permutation test (two-tailed) with Benjamini–Hochberg correction. Data are presented as mean ± SEM. Individual values are presented as small dots and each circle represents an average of one mouse; individual values and averages are color codedCC BY · PubMed Central
Fig. 3 Partial microglia depletion by low-dose PLX5622 prevents acute and long-term microgliosis after polymicobial sepsis. A Representative confocal images of microglia in the CA1 region of the hippocampus at day 38. Scale bar 200 µm, zoom-in 20 µm. B Quantitative analysis of Iba1-positive microglia in the CA1 region of the hippocampus following AIN or low-dose PLX5622 pretreatment and systemic inflammation by PCI at day 3 (AIN-sham: n = 7, AIN-PCI: n = 6; PLX5622-sham: n = 7, PLX5622-PCI: n = 6; n = 3 images/animal, Two-way ANOVA with post hoc Tukey test). C Quantitative analysis of Iba1-positive microglia in the CA1 region of the hippocampus at day 38 following AIN or low-dose PLX5622 pretreatment and systemic inflammation by PCI (n = 5 animals/group, n = 4 images/animal, Two-way ANOVA with post hoc Tukey test). Data are presented as mean ± SEM. Individual values are presented as small dots and each circle represents an average of one mouse; individual values and averages are color coded.
Fig. 3 Partial microglia depletion by low-dose PLX5622 prevents acute and long-term microgliosis after polymicobial sepsis. A Representative confocal images of microglia in the CA1 region of the hippocampus at day 38. Scale bar 200 µm, zoom-in 20 µm. B Quantitative analysis of Iba1-positive microglia in the CA1 region of the hippocampus following AIN or low-dose PLX5622 pretreatment and systemic inflammation by PCI at day 3 (AIN-sham: n = 7, AIN-PCI: n = 6; PLX5622-sham: n = 7, PLX5622-PCI: n = 6; n = 3 images/animal, Two-way ANOVA with post hoc Tukey test). C Quantitative analysis of Iba1-positive microglia in the CA1 region of the hippocampus at day 38 following AIN or low-dose PLX5622 pretreatment and systemic inflammation by PCI (n = 5 animals/group, n = 4 images/animal, Two-way ANOVA with post hoc Tukey test). Data are presented as mean ± SEM. Individual values are presented as small dots and each circle represents an average of one mouse; individual values and averages are color coded.CC BY · PubMed Central
Fig. 4 Partial microglia depletion by low-dose PLX5622 prevents acute astrogliosis after polymicobial sepsis. A Representative confocal images of astrocytes in the CA1 region of the hippocampus at day 3. Scale bar 200 µm, zoom-in 20 µm. B Quantitative analysis of GFAP-positive astrocytes in the CA1 region of the hippocampus following AIN or low-dose PLX5622 pretreatment and systemic inflammation by PCI at day 3 (n = 5 animals/group, n = 3 images/animal, Two-way ANOVA with post hoc Tukey test). C Quantitative analysis of GFAP-positive astrocytes in the CA1 region of the hippocampus at day 38 following AIN or low-dose PLX5622 pretreatment and systemic inflammation by (n = 5 animals/group, n = 2 images/animal, Two-way ANOVA with post hoc Tukey test). Data are presented as mean ± SEM. Individual values are presented as small dots and each circle represents an average of one mouse; individual values and averages are color coded
Fig. 4 Partial microglia depletion by low-dose PLX5622 prevents acute astrogliosis after polymicobial sepsis. A Representative confocal images of astrocytes in the CA1 region of the hippocampus at day 3. Scale bar 200 µm, zoom-in 20 µm. B Quantitative analysis of GFAP-positive astrocytes in the CA1 region of the hippocampus following AIN or low-dose PLX5622 pretreatment and systemic inflammation by PCI at day 3 (n = 5 animals/group, n = 3 images/animal, Two-way ANOVA with post hoc Tukey test). C Quantitative analysis of GFAP-positive astrocytes in the CA1 region of the hippocampus at day 38 following AIN or low-dose PLX5622 pretreatment and systemic inflammation by (n = 5 animals/group, n = 2 images/animal, Two-way ANOVA with post hoc Tukey test). Data are presented as mean ± SEM. Individual values are presented as small dots and each circle represents an average of one mouse; individual values and averages are color codedCC BY · PubMed Central
Fig. 5 Partial microglia depletion by low-dose PLX5622 prevents sepsis-induced synaptic elimination. A Representative 3D reconstructions and Airyscan processed confocal images of Homer1 postsynaptic terminals colocalized with Iba1-positive microglia. Scale bar 10 µm, 1 µm and 2 µm. B Quantitative analysis of colocalized Homer1 puncta and Iba1-positive microglia indicating synaptic engulfment or attachment of postsynaptic terminals by microglia in early systemic inflammation on day 3 (n = 4–6 animals/group, n = 3–4 microglia/animal, Two-way ANOVA with post hoc Tukey test). C Quantitative analysis of colocalized Homer1 puncta and Iba1-positive microglia indicating synaptic engulfment or attachment of postsynaptic terminals by microglia in chronic systemic inflammation on day 38 (n = 5 animals/group, n = 2 microglia/animal, Two-way ANOVA with post hoc Tukey test). Data are presented as mean ± SEM. Individual values are presented as small dots and each circle represents an average of one mouse; individual values and averages are color coded
Fig. 5 Partial microglia depletion by low-dose PLX5622 prevents sepsis-induced synaptic elimination. A Representative 3D reconstructions and Airyscan processed confocal images of Homer1 postsynaptic terminals colocalized with Iba1-positive microglia. Scale bar 10 µm, 1 µm and 2 µm. B Quantitative analysis of colocalized Homer1 puncta and Iba1-positive microglia indicating synaptic engulfment or attachment of postsynaptic terminals by microglia in early systemic inflammation on day 3 (n = 4–6 animals/group, n = 3–4 microglia/animal, Two-way ANOVA with post hoc Tukey test). C Quantitative analysis of colocalized Homer1 puncta and Iba1-positive microglia indicating synaptic engulfment or attachment of postsynaptic terminals by microglia in chronic systemic inflammation on day 38 (n = 5 animals/group, n = 2 microglia/animal, Two-way ANOVA with post hoc Tukey test). Data are presented as mean ± SEM. Individual values are presented as small dots and each circle represents an average of one mouse; individual values and averages are color codedCC BY · PubMed Central
Fig. 6 Partial microglia depletion by low-dose PLX5622 rescues from long-term neurocognitive deficits. A Schematic NOR test procedure: Mice were familiarized with two identical objects during familiarization. After 6 h intersession interval one object was replaced by the novel object and the exploration time of the novel object was investigated. B, C NOR test was performed at day 10 (AIN-sham: n = 7, AIN-PCI: n = 11; PLX5622-sham: n = 7, PLX5622-PCI: n = 10, Two-way ANOVA with post hoc Tukey test) and day 30 (AIN-sham: n = 6, AIN-PCI: n = 9; PLX5622-sham: n = 7, PLX5622-PCI: n = 10, Two-way ANOVA with post hoc Tukey test). D Schematic OF test procedure: Mice explored the OF freely and mean velocity has been measeured. E, F Open field was performed to analyze the locomotor activity at day 9 (AIN-sham: n = 6, AIN-PCI: n = 10; PLX5622-sham: n = 5, PLX5622-PCI: n = 8, Two-way ANOVA with post hoc Tukey test) and day 29 (AIN-sham: n = 7, AIN-PCI: n = 11; PLX5622-sham: n = 7, PLX5622-PCI: n = 10, Two-way ANOVA with post hoc Tukey test). Data are presented as mean ± SEM. Each circle represents one mouse
Fig. 6 Partial microglia depletion by low-dose PLX5622 rescues from long-term neurocognitive deficits. A Schematic NOR test procedure: Mice were familiarized with two identical objects during familiarization. After 6 h intersession interval one object was replaced by the novel object and the exploration time of the novel object was investigated. B, C NOR test was performed at day 10 (AIN-sham: n = 7, AIN-PCI: n = 11; PLX5622-sham: n = 7, PLX5622-PCI: n = 10, Two-way ANOVA with post hoc Tukey test) and day 30 (AIN-sham: n = 6, AIN-PCI: n = 9; PLX5622-sham: n = 7, PLX5622-PCI: n = 10, Two-way ANOVA with post hoc Tukey test). D Schematic OF test procedure: Mice explored the OF freely and mean velocity has been measeured. E, F Open field was performed to analyze the locomotor activity at day 9 (AIN-sham: n = 6, AIN-PCI: n = 10; PLX5622-sham: n = 5, PLX5622-PCI: n = 8, Two-way ANOVA with post hoc Tukey test) and day 29 (AIN-sham: n = 7, AIN-PCI: n = 11; PLX5622-sham: n = 7, PLX5622-PCI: n = 10, Two-way ANOVA with post hoc Tukey test). Data are presented as mean ± SEM. Each circle represents one mouseCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 1

  1. Grünewald B, Wickel J, Hahn N, Hörhold F, Rupp H, Chung H-Y, et al. Targeted rescue of synaptic plasticity improves cognitive decline after severe systemic inflammation. bioRxiv. 2021;30416:1787.

Cited by

See all 37

Metadata

Authors
Mein, N., von Stackelberg, N., Wickel, J., Geis, C., & Chung, H.-Y.
Affiliations
Jena University Hospital (DE)
Corresponding author
Chung, Ha-Yeun
Venue
Journal of Neuroinflammation
Published
2023-12-01
Volume
20
Issue
1
Pages
289-289
ISSN
1742-2094 (ISSN-L)
OpenAlex
W4389242689
Cited by
36
References
48
Citations by year
2026: 12 · 2025: 15 · 2024: 9
FWCI
3.70
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Neuroinflammation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Common Library Network (Der Gemeinsame Bibliotheksverbund) (submittedVersion, cc-by)
Funders
  • Interdisciplinary Center of Clinical Research
  • Center for Sepsis Control and Care, Jena, Germany
  • German Research Council (GE2519/8-1, GE2519/9-1)
  • Schilling Foundation
  • German Center for Mental Health; Center for Intervention and Research on adaptive and maladaptive brain Circuits underlying mental health (C-I-R-C), Jena-Magdeburg-Halle, Germany
  • Universitätsklinikum Jena
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Keywords
PLX5622, CSF1R inhibition, sepsis-associated encephalopathy, microglia depletion, neuroinflammation, neurocognitive decline, hippocampus-dependent learning, novel object recognition, Homer1, astrocyte activation, microglial activation, lipopolysaccharide-induced neuroinflammation, polymicrobial sepsis
MeSH terms
Neuroinflammatory Diseases, Animals, Macrophages, Male, Organic Chemicals, Receptors, Colony-Stimulating Factor, Microglia, Sepsis, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low-dose PLX5622 treatment prevents neuroinflammatory and neurocognitive sequelae after sepsis. https://app.cochat.ai/papers/10.1186/s12974-023-02975-8
The paper
Mein, N., von Stackelberg, N., Wickel, J., Geis, C., & Chung, H.-Y. (2023). Low-dose PLX5622 treatment prevents neuroinflammatory and neurocognitive sequelae after sepsis. Journal of Neuroinflammation. https://doi.org/10.1186/s12974-023-02975-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.